Regeneron pharmaceuticals (regn) faces securities class action after losing $9 billion value following q3 2024 earnings report - hagens berman

Regn investors with losses encouraged to contact the firm san francisco, ca / access newswire / january 21, 2025 / regeneron pharmaceuticals, inc. (nasdaq:regn) faces a securities fraud class action after shares of the company plunged $84.59 on oct. 31, 2024, wiping out about $9 billion of market value. hagens berman has opened an investigation into whether regeneron may have misled investors about its marketing and reimbursement practices related to its eylea® product, an injection to treat age-related macular degeneration by inhibiting anti vascular endothelial growth factor ("anti-vegf"), and urges investors who purchased regeneron shares and suffered substantial losses to submit your losses now.
REGN Ratings Summary
REGN Quant Ranking